2OFV

crystal structure of aminoquinazoline 1 bound to Lck


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.00 Å
  • R-Value Free: 0.301 
  • R-Value Work: 0.274 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity

DiMauro, E.F.Newcomb, J.Nunes, J.J.Bemis, J.E.Boucher, C.Buchanan, J.L.Buckner, W.H.Cee, V.J.Chai, L.Deak, H.L.Epstein, L.F.Faust, T.Gallant, P.Geuns-Meyer, S.D.Gore, A.Gu, Y.Henkle, B.Hodous, B.L.Hsieh, F.Huang, X.Kim, J.L.Lee, J.H.Martin, M.W.Masse, C.E.McGowan, D.C.Metz, D.Mohn, D.Morgenstern, K.A.Oliveira-dos-Santos, A.Patel, V.F.Powers, D.Rose, P.E.Schneider, S.Tomlinson, S.A.Tudor, Y.-Y.Turci, S.M.Welcher, A.A.White, R.D.Zhao, H.Zhu, L.Zhu, X.

(2006) J Med Chem 49: 5671

  • DOI: https://doi.org/10.1021/jm0605482
  • Primary Citation of Related Structures:  
    2OFV, 2OG8

  • PubMed Abstract: 

    The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Optimized, orally bioavailable compounds 32 and 47 exhibit anti-inflammatory activity (ED(50) of 22 and 11 mg/kg, respectively) in the anti-CD3-induced production of interleukin-2 (IL-2) in mice.


  • Organizational Affiliation

    Department of Medicinal Chemistry, Amgen, Inc., Cambridge, Massachusetts 02139, USA. edimauro@amgen.com


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Proto-oncogene tyrosine-protein kinase LCK
A, B
277Homo sapiensMutation(s): 0 
Gene Names: LCK
EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for P06239 (Homo sapiens)
Go to UniProtKB:  P06239
PHAROS:  P06239
GTEx:  ENSG00000182866 
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
242
Query on 242

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
C23 H17 F3 N4 O
YEIASMOUYNOXGA-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
242 PDBBind:  2OFV IC50: 0.2 (nM) from 1 assay(s)
BindingDB:  2OFV IC50: min: 0.2, max: 1 (nM) from 2 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.00 Å
  • R-Value Free: 0.301 
  • R-Value Work: 0.274 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 142.66α = 90
b = 66.89β = 112
c = 78.51γ = 90
Software Package:
Software NamePurpose
AMoREphasing
CNSrefinement
DENZOdata reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Released Date: 2007-02-27 
  • Deposition Author(s): Huang, X.

Revision History  (Full details and data files)

  • Version 1.0: 2007-02-27
    Type: Initial release
  • Version 1.1: 2008-05-01
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2023-08-30
    Changes: Data collection, Database references, Derived calculations, Refinement description